OTC CGM at Walmart; California’s Own Insulin; Ozempic’s Price Negotiations UnderwayOTC CGM at Walmart; California’s Own Insulin; Ozempic’s Price Negotiations Underway
(MedPage Today) — Walmart will be the first physical U.S. retailer to carry Abbott’s over-the-counter (OTC) continuous glucose monitor (CGM). (Axios) Very few U.S. adults have heard of cardiovascular-kidney-metabolic syndrome despite almost 90… (MedPage Today) — Walmart will be the first physical U.S. retailer to carry Abbott’s over-the-counter (OTC) continuous glucose monitor (CGM). (Axios) Read More
AI model combines clinical and magnetic resonance data to improve prediction of breast cancer recurrenceAI model combines clinical and magnetic resonance data to improve prediction of breast cancer recurrence
Breast cancer is the most commonly diagnosed form of cancer in the world among women, with more than 2.3 million cases a year, and continues to be one of the main causes of cancer-related mortality. Precisely predicting whether this type of tumor will reappear remains one of the key challenges in oncology.
Clinical Highlights From ESC 2025—GLP-1 Drugs in Heart Failure and MoreClinical Highlights From ESC 2025—GLP-1 Drugs in Heart Failure and More
This Medical News article is an interview with Felix Mahfoud, MD, chair of the Department of Cardiology at University Hospital Basel, about clinical highlights from the European Society of Cardiology Congress held recently in Madrid. This Medical News article is an interview with Felix Mahfoud, MD, chair of the Department of Cardiology at University Hospital Read More
GLP-1 Drugs May Manage Weight Recurrence After Bariatric SurgeryGLP-1 Drugs May Manage Weight Recurrence After Bariatric Surgery
Glucagon-like peptide-1 (GLP-1) receptor agonists may support weight management in patients following bariatric surgery. A study suggests that GLP-1 drug use is particularly common among those with less postsurgical weight loss. Glucagon-like peptide-1 (GLP-1) receptor agonists may support weight management in patients following bariatric surgery. A study suggests that GLP-1 drug use is particularly common Read More
Obesity-related cancer rising among both younger and older adults worldwide, study findsObesity-related cancer rising among both younger and older adults worldwide, study finds
A surveillance study compared international cancer incidence trends of 13 cancer types in younger and older adults.
Mortality down with GLP-1 receptor agonist use in T2D, especially in those with OSAMortality down with GLP-1 receptor agonist use in T2D, especially in those with OSA
Patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly lower one-year mortality, especially those also diagnosed with obstructive sleep apnea (OSA), according to a study presented at CHEST 2025, the annual meeting of the American College of Chest Physicians, held from Oct. 19 to 22 in Chicago. Patients Read More
FDA Approves GLP-1 Pill for Primary, Secondary Cardiovascular ProtectionFDA Approves GLP-1 Pill for Primary, Secondary Cardiovascular Protection
(MedPage Today) — The FDA approved oral semaglutide (Rybelsus) to prevent major adverse cardiovascular events (MACE) in high-risk patients with diabetes, whether or not they’ve had such an event already, Novo Nordisk announced. Semaglutide 7… (MedPage Today) — The FDA approved oral semaglutide (Rybelsus) to prevent major adverse cardiovascular events (MACE) in high-risk patients Read More
De-Escalating Bone-Modifying Therapy Safe, Effective in Metastatic Breast CancerDe-Escalating Bone-Modifying Therapy Safe, Effective in Metastatic Breast Cancer
(MedPage Today) — BERLIN — Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for patients with bone metastases from breast cancer, and also appeared to be safe in prostate cancer…
Breastfeeding causes a surge in immune cells that could prevent cancerBreastfeeding causes a surge in immune cells that could prevent cancer
Breastfeeding seems to cause specialised immune cells to flood into the breasts and stay there for years or even decades, reducing the risk of cancer
New generation of antibody-drug conjugates shows promise in early-stage HER2-positive breast cancerNew generation of antibody-drug conjugates shows promise in early-stage HER2-positive breast cancer
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer.